These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1298 related items for PubMed ID: 31432594

  • 1. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
    Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K.
    Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
    [Abstract] [Full Text] [Related]

  • 2. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS, Qu Y, MacMullan M, Chen X, Cinay G, Wang P.
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE, Yu J, Wang Y, Wang H, Wang J, Wang Y, Yu L, Yan Z.
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [Abstract] [Full Text] [Related]

  • 8. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
    Harrasser M, Gohil SH, Lau H, Della Peruta M, Muczynski V, Patel D, Miranda E, Grigoriadis K, Grigoriadis A, Granger D, Evans R, Nathwani AC.
    Breast Cancer Res; 2022 Jun 03; 24(1):39. PubMed ID: 35659040
    [Abstract] [Full Text] [Related]

  • 9. Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.
    Hombach AA, Rappl G, Abken H.
    Mol Ther; 2019 Oct 02; 27(10):1825-1835. PubMed ID: 31331813
    [Abstract] [Full Text] [Related]

  • 10. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A, Sun Y, Wang S, Du J, Gao X, Yuan Y, Zhao L, Yang Y, Xu L, Lei Y, Duan L, Xu C, Ma L, Wang J, Hu G, Chen H, Wang Q, Hu L, Zhang B.
    Cytotherapy; 2020 Dec 02; 22(12):734-743. PubMed ID: 32684339
    [Abstract] [Full Text] [Related]

  • 11. Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model.
    Song Y, Liu Q, Zuo T, Wei G, Jiao S.
    Cell Immunol; 2020 Jun 02; 352():104112. PubMed ID: 32305131
    [Abstract] [Full Text] [Related]

  • 12. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X.
    Hum Immunol; 2021 Feb 02; 82(2):130-138. PubMed ID: 33341289
    [Abstract] [Full Text] [Related]

  • 13. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K.
    Cancer Immunol Immunother; 2021 Sep 02; 70(9):2503-2515. PubMed ID: 33559069
    [Abstract] [Full Text] [Related]

  • 14. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
    Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, Yan S, Xiang J, Ma X, Seshan VE, Hendrickson RC, Liu C, Brentjens RJ.
    Nat Biotechnol; 2018 Oct 02; 36(9):847-856. PubMed ID: 30102295
    [Abstract] [Full Text] [Related]

  • 15. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B, Luo L, Wang J, He B, Feng R, Xian N, Zhang Q, Chen L, Huang G.
    Oncoimmunology; 2020 Oct 02; 9(1):1684127. PubMed ID: 32002297
    [Abstract] [Full Text] [Related]

  • 16. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide.
    Yang P, Wang Y, Yao Z, Gao X, Liu C, Wang X, Wu H, Ding X, Hu J, Lin B, Li Q, Li M, Li X, Chen X, Qi W, Li W, Xue J, Xu H.
    J Am Chem Soc; 2020 Nov 04; 142(44):18874-18885. PubMed ID: 32966054
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X.
    Hum Gene Ther; 2019 Apr 04; 30(4):446-458. PubMed ID: 29706119
    [Abstract] [Full Text] [Related]

  • 20. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct 04; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.